Indeed, immunocompetent mice bearing tumors treated with an EZH2 inhibitor show a significant decrease in tumor volume compared to mice deficient in T cells, suggesting an interplay between EZH2 and the T cell immune response.190 Tregs promote tumor progression in an EZH2-dependent manner by producing immunosuppressive cytokines and preventing recruitment of T CDC8+. Here, DTYMK is linked to neoplasm.